



**NATURAL
CAPSULES
LIMITED**



CORP & REGD OFFICE : "TRIDENT TOWERS" No. 23, 4th Floor, 100 feet Road, Jayanagar 2nd Block, Bangalore-560011
Phone : 080-26561562 / 1571 /1573 /581 URL : www.naturalcapsules.com Email : info@naturalcapsules.com, CIN No. : L85110KA1993PLC014742

Date: 08.02.2022

To,
M/s. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai-400001
Security Code: 524654

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on February 08, 2022

This is to inform that the Board of the Directors at their meeting held today, i.e. Tuesday, February 08, 2022, inter alia has transacted the following:

1. Adoption of Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2021.

Further in compliance with regulation 33 of SEBI (Listing Obligations and Disclosures Requirements), Regulations 2015, we submit herewith, the Unaudited Standalone and Consolidated financial results along with Limited Review Report for the quarter ended December 31, 2021.

The Board Meeting commenced at 04.00 PM and concluded at 06.00 PM.

Kindly take the aforesaid information on record in compliance of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Thanking you.

For Natural Capsules Limited


Shilpa Burman
Company Secretary & Compliance Officer



P. CHANDRASEKAR LLP

Chartered Accountants

Limited Review Report on unaudited quarterly consolidated financial results and consolidated year-to-date results under Regulation 33 of the Listing Regulations

To
The Board of Directors
Natural Capsules Limited
Bangalore- 560011.

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Natural Capsules Limited** ("the parent") and its Subsidiaries(the parent and its subsidiaries together referred to as "the group") for the Quarter ended 31st December 2021 and year to date results for the period from 01 April 2021 to 31st December 2021 , being submitted by the parent pursuant to the requirements of Regulation 33 of SEBI (Listing obligations and Disclosure requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and has been approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34 "Interim Financial Reporting"("Ind AS 34"), prescribed under section 133 of companies act,2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Natural Phyto Pharma Private Limited	Subsidiary
Natural Biogenex Private Limited	Subsidiary



Bangalore * Chennai


S-512-514, Manipal Centre, # 47, Dikenson Road, Bangalore - 560042. T: +91 (80) 25585443 / 25597494 E-mail: partner@pchandrasekar.com

M/s P. Chandrasekar (Partnership Firm) is converted into P. Chandrasekar LLP (a Limited Liability Partnership with LLP Identity No. LLPIN AAJ-5668) with effect from 31.05.2017

5. The accompanying statement includes the interim financial results and other financial information in-respect of one subsidiary, whose interim financial results /information reflects total revenues of Rs. nil , net loss after tax and total comprehensive income 3.04 lakhs for the quarter ended 31st December, 2021 and Rs.Rs.6.31 lakhs year to date from April 01, 2021 to December 31, 2021 respectively, which have been reviewed by us.
6. We did not review the interim financial results of one subsidiary Natural Phyto Pharma Private Limited included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs.1.61 lacs as at 31st December 2021 and total revenues of Rs. Nil for the quarter ended 31st December 2021, total net profit after tax of Rs. Nil for the quarter ended 31st December 2021 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.
7. Based on our review conducted as above and based on the consideration of the review financial results/financial information certified by the Management as given above in point no.6, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable Indian accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bangalore
Date: 08th February 2022

For P Chandrasekar LLP
Chartered Accountants
(Firm Regn. No.000580S/S200066)



S. Rajagopalan
Partner
Membership No. 025349
UDIN:




22025349AAWATL 2296

NATURAL CAPSULES LIMITED
 TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
 Ph. 26671571/573, Fax 26671562, E-mail : info@naturalcapsules.com / CIN: L85110KAI993PLCO14742
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR QUARTER/NINE MONTHS ENDED DECEMBER, 2021

Remarks

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended			Year Ended
		31st December 2021	30th September 2021	31st December 2020	31st December 2021	31st December 2020	31st March 2021	
1	Revenue from operations	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
2	Other Income	3,761	3,020	2,175	9,352	5,640	7,951	7,951
3	Total Income (1+2)	6	10	2	20	53	53	73
4	Expenses	3,767	3,030	2,176	9,372	5,693	5,693	8,024
	a) Cost of Material consumed	1,574	1,384	994	3,988	2,584	3,610	3,610
	b) (Increase) / Decrease in stock in trade	15	1	33	(63)	107	133	133
	c) Purchase of stock-in-trade	-	-	-	195	-	-	-
	d) Employees benefits expense	265	226	212	725	572	805	805
	e) Finance cost	57	46	3	129	21	37	37
	f) Depreciation	125	123	109	364	318	431	431
	g) Other Expenses	1,142	877	600	2,781	1,656	2,311	2,311
	Total Expenses	3,176	2,657	1,950	8,121	5,238	7,326	7,326
5	Profit from ordinary activities after finance costs but before exceptional items	591	373	226	1,231	455	698	698
6	Exceptional Items Income / (Expenses)	-	-	-	-	218	218	218
7	Profit from ordinary activities before tax	181	112	226	1,231	673	916	916
8	Tax Expense	165	85	55	325	169	222	222
	- Current Tax	-	-	-	-	-	-	-
	- Income tax (Prior year)	17	27	9	46	(24)	2	2
9	Net Profit (+) / Loss (-) from ordinary activities after tax	410	261	162	880	528	691	691
10	Other Comprehensive Income (OCI)	-	-	-	-	-	(6)	(6)
11	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-	-
11	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-	-
12	Total Comprehensive Income (OCI) for the period	410	261	162	880	528	685	685
13	Paid-Up Equity Share Capital (face value per share Rs. 10/-)	701	623	623	701	623	623	623
	Earnings Per Share of (Before & after extraordinary items) Rs. 10/-	5.85	4.18	2.59	12.55	8.47	10.99	10.99
	(a) Basic	5.85	4.18	2.59	12.55	8.47	10.99	10.99
	(b) Diluted	5.85	4.18	2.59	12.55	8.47	10.99	10.99
	Note:							
1	The unaudited Consolidated financial results of the Group for the Quarter and Nine months Ended 31st December 2021 have been approved by the Board of Directors of the Company at its meeting held on 1st February, 2022. The figures for the Quarter ended 31st December 2021 was subject to Limited Review by Statutory Auditors of the Company who have expressed an unqualified review opinion.							
2	The Unaudited Consolidated Financial results for the Quarter and Nine month Ended 31st December 2021 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above Unaudited Consolidated Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.							
3	The Holding company, vide Letter of Offer filed with the Stock Exchange on August 24, 2021 and the In-Principle Approval of BSE Limited (BSE), vide letter dated September 08, 2021 which opened for subscription on November 30, 2021 and closed on December 20, 2021 for existing shareholder as on record date i.e. November 12, 2021 for 31,16,350 Rights equity shares of face value of Rs. 10.00 (of which Rs. 2,50 being called up) ("Rights Equity Shares") at an issue Price of Rs. 100.00 - per Equity Share (of which Rs. 25 being called up). The Holding company has allotted shares in the ratio of 1 rights equity shares for every 2 fully paid-up equity shares held by the eligible equity shareholders on the record date, i.e. November 12, 2021.							
4	During the quarter the Holding company has received Rs 712.69 lacs as first call of Rs. 25 per rights equity shares (including premium of Rs. 22.50 per share). An amount of Rs. 66 lacs is receivable towards call money as on 31st December 2021. There is no deviation in the use of proceeds from the objects stated in the offer documents for the rights issue.							
5	Previous years figures have been regrouped wherever necessary.							
6	Position of investor complaints for the quarter ended 31st December 2021							
	Particulars							
	Pending as on 30-09-2021							
	Received during the quarter							
	Resolved during the quarter							
	Pending as on 31-12-2021							
	Place : Bangalore							
	Date : 08-02-2022							



P. CHANDRASEKAR LLP

Chartered Accountants

LIMITED REVIEW REPORT

The Board of Directors
Natural capsules Limited
Bangalore – 560011.

We have reviewed the accompanying statement of unaudited Standalone financial results ("the Statement") of **Natural Capsules Limited** ("the Company") for the Quarter and Nine Months ended 31st December 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bangalore
Date: 08th February 2022

For P Chandrasekar LLP
Chartered Accountants
(Firm Regn. No.000580S/S200066)



S. Rajagopalan
Partner
Membership No. 025349
UDIN 22025349AA 2M 17687



Bangalore * Chennai

UNAUDITED STANDALONE FINANCIAL RESULTS FOR QUARTER/ NINE MONTHS ENDED DECEMBER,2021

Rs.in Lacs

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31st December 2021	30th September 2021	31st December 2020	31st December 2021	31st December 2020	31st March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	3,761	3,020	2,175	9,352	5,640	7,951
2	Other Income	6	10	2	20	53	73
3	Total Income (1+2)	3,767	3,030	2,176	9,372	5,693	8,024
4	Expenses						
	a) Cost of Material consumed	1,574	1,384	994	3,988	2,584	3,610
	b) (Increase) / Decrease in stock in trade	15	1	33	(63)	107	133
	c) Purchase of stock-in-trade	-	-	-	195	-	-
	d) Employees benefits expense	263	226	212	725	572	805
	f) Finance cost	57	46	3	129	21	37
	g) Depreciation	125	123	109	364	318	431
	h) Other Expenses	1,139	875	600	2,775	1,636	2,307
	Total Expenses	3,173	2,655	1,950	8,114	5,238	7,323
	Profit from ordinary activities after finance costs but before exceptional items	594	375	226	1,257	455	701
5	Exceptional Items Income / (Expenses)	-	-	-	-	218	218
6	Profit from ordinary activities before tax	594	375	226	1,257	673	919
7	Tax Expense	181	112		371	145	224
	- Current Tax	165	85	55	325	169	222
	- Income tax (Prior year)	-	-	-	-	-	-
	- Deferred Tax	17	27	9	46	(24)	2
8	Net Profit (+) / Loss (-) from ordinary activities after tax	413	263	162	886	528	695
9	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	(6)
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
10	Total Comprehensive Income (OCI) for the period	413	263	162	886	528	688
11	Paid-Up Equity Share Capital (face value per share Rs.10/-)	701	623	623	701	623	623
12	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	5.89	4.21	2.59	12.64	8.47	11.04
	(b) Diluted	5.89	4.21	2.59	12.64	8.47	11.04

Note:

- The unaudited standalone financial results of the Company for the Quarter and Nine months Ended 31st December 2021 have been approved by the Board of Directors of the Company at its meeting held on 1st February, 2022. The figures for the Quarter ended 31st December 2021 was subject to 'Limited Review' by Statutory Auditors of the Company who have expressed an unqualified review opinion.
- The Unaudited Standalone Financial results for the Quarter and Nine month Ended 31st December 2021 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above Unaudited Standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- The company, vide Letter of Offer filed with the Stock Exchange on August 24, 2021, and the In-Principle Approval of BSE Limited (BSE), vide letter dated September 08, 2021 which opened for subscription on November 30, 2021 and closed on December 20, 2021 for existing shareholder as on record date i.e. November 12, 2021 for 31,16,350 Rights equity shares of face value of Rs. 10.00 (of which Rs. 2.50 being called up) ("Rights Equity Shares") at an issue Price of Rs. 100.00 per Equity Share (including a premium of Rs.90 per share and of which Rs. 25 being called up). The company has allotted shares in the ratio of 1 rights equity shares for every 2 fully paid-up equity shares held by the eligible equity shareholders on the record date, i.e. November 12, 2021.
- During the quarter the company has received Rs.712.69 lacs as first call of Rs.25 per rights equity shares (including premium of Rs.22.50 per share). An amount of Rs.66 lacs is receivable toward call money as on 31st December 2021. There is no deviation in the use of proceeds from the objects stated in the offer documents for the rights issue
- Previous years figures have been regrouped wherever necessary.
- Position of investor complaints for the quarter ended 31st December 2021

Particulars	
Pending as on 30-09-2021	Nil
Received during the quarter	1
Resolved during the quarter	1
Pending as on 31-12-2021	Nil

Place : Bangalore
Date : 08-02-2022

